Format

Send to

Choose Destination
Biochem Pharmacol. 2004 Oct 15;68(8):1537-40.

GABA pharmacology--what prospects for the future?

Author information

1
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX13QT, UK. les.iversen@pharm.ox.ac.uk

Abstract

Following the recognition of GABA as an inhibitory neurotransmitter, the discovery of high affinity GABA uptake, and the characterisation of GABA receptors great progress has been made in developing GABA pharmacology. Tiagabide, the first marketed GABA uptake inhibitor may be followed by new and more selective uptake inhibitors. Knowledge of the molecular pharmacology of GABA-A receptors, both synaptic and non-synaptic, may lead to improved anti-anxiety/anticonvulsant agents devoid of the sedative and dependence liabilities of earlier compounds and new hypnotics. Gaboxadol (THIP) is an example of a novel hypnotic that acts on GABA-A receptors by a non-benzodiazepine mechanism. Exploiting neurosteroid interactions with GABAergic mechanisms also holds much future promise.

PMID:
15451396
DOI:
10.1016/j.bcp.2004.06.039
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center